Antonia Salud Salvia

Salud, A.; Escudero, P.; Feliu, J.; Lopez-Gomez, L.; Bolanos, M.; Galan, A.; Yubero, A.; Vicent, J. M.; Losa, F.; Gonzalez-Baron, M.

Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)

Ejc Supplements 3 190-190. 01/10/2005.

Saigi, E; Batiste-Alentorn, E; Diaz, N; Galan, A; Salud, A; Campos, JM; Losa, F; Gallen, M; Massuti, B; Asensio, D

Phase II study of weekly irinotecan (CPT-11) associated to protracted oral tegafur (TGF) in previously untreated, advanced colorectal cancer (aCRC)

Journal of Clinical Oncology 23 302-302. 01/06/2005.

Alonso, V; Salud, A; Escudero, P; Bueso, P; Mira, M; Valencia, J; Polo, S; de Lobera, AR; Lao, J; Lastra, R

Phase II trial of preoperative chemoradiotherapy with irinotecan and infusional 5-fluorouracil in locally advanced operable rectal carcinoma.

Journal of Clinical Oncology 23 256-256. 01/06/2005.

Salud, A; Escudero, P; Feliu, J; Lopez-Gomez, L; Bolanos, M; Galan, A; Yubero, A; Vicent, JM; Losa, F; Baron, MG

XELOX (capecitabine and axaliplatin) as 1(st) line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC).

Journal of Clinical Oncology 23 276-276. 01/06/2005.

Hough, CL; Hudson, LD; Salud, A; Lahey, T; Curtis, JR

Death rounds: end-of-life discussions among medical residents in the intensive care unit

JOURNAL OF CRITICAL CARE 20 20-25. 01/03/2005.

[doi:10.1016/j.jcrc.2004.09.006]

Porcel, JM; Vives, M; Esquerda, A; Salud, A; Perez, B; Rodriguez-Panadero, F

Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.

Chest 126 1757-1763. 01/12/2004.

[doi:10.1378/chest.126.6.1757]

Salud, A; Saigi, E; Batiste-Alentorn, B; Losa, F; Cirera, L; Mendez, M; Campos, JM; Galan, A; Escudero, MP; Nogue, M

Randomized phase IV trial of oral tegafur and low dose leucovorin versus intravenous 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer (aCC): Final results.

Journal of Clinical Oncology 22 3547-3547. 15/07/2004.

Gravalos, C; Garcia-Giron, C; Leon, AI; Salud, A; Esteban, B; Sevilla, I; Maurel, J; Murias, A; Garcia-Rico, E; Cortes-Funes, HG

TOMOX compared to FOLFOX4 as first-line treatment in patients (pts) with advanced colorectal cancer (aCRC): Preliminary results of a multicenter randomized phase II trial.

Journal of Clinical Oncology 22 3599-3599. 15/07/2004.

Munoz, A; Salud, A; Alonso, V; Escudero, P; Sanz, JJ; Martin, C; Rivera, F; Yubero, A; Garcia-Giron, C; Lopez-Vivanco, G

Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (La) or metastatic colorectal cancer (MCRC).

Journal of Clinical Oncology 22 3610-3610. 15/07/2004.

Alonso, V; Salud, A; Escudero, P; Valencia, J; Mira, M; de Lobera, AR; Lambea, J; Grandez, R; Tres, A; Anton, A

Preoperative chemoradiation with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma.

Journal of Clinical Oncology 22 3607-3607. 15/07/2004.

Lopez-Gomez, L; Escudero, P; Yubero, A; Feliu, J; Salud, A; Galan, A; Bolanos, M; Vicent, JM; Losa, F; Gonzalez-Baron, M

XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC).

Journal of Clinical Oncology 22 3688-3688. 15/07/2004.

Feliu, J; Salud, A; Escudero, P; Lopez-Gomez, L; Pericay, C; Castanon, C; de Tejada, MRL; Rodriguez-Garcia, JM; Martinez, MP; Martin, MS; Sanchez, JJ; Baron, MG

Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study

BRITISH JOURNAL OF CANCER 90 1502-1507. 19/04/2004.

[doi:10.1038/sj.bjc.6601713]